Biohaven is a clinical-stage biopharmaceutical company with proven leadership in industry and academic settings. Our portfolio is comprised of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders. Our progress is fueled by an entrepreneurial organizational structure and an impressive range of experience in drug development along with the confident support of top-tier biopharma investors.
Since our initial public offering in 2017 we have made rapid progress with multiple compounds. We are poised to achieve a number of clinical and regulatory milestones, most recently with the FDA approval of Nurtec ODT (rimegepant), a novel, orally-dosed migraine treatment. In addition, multiple clinical trials across product candidates are ongoing.
Brands: Nurtec ODT